Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data
Andrew Kuykendall, Libo Sun, John Mascarenhas, Jean‐Jacques Kiladjian, Alessandro M. Vannucchi, Julia Wang, Qi Xia, Eugene Zhu, Faye Feller, Aleksandra Rizo, Jacqueline Bussolari, Ying Wan, Rami S. Komrokji
Topics & Concepts
RuxolitinibMedicineInternal medicineMyelofibrosisHazard ratioPopulationContext (archaeology)Propensity score matchingCohortDiscontinuationSurgeryOncologyConfidence intervalBone marrowBiologyPaleontologyEnvironmental healthMyeloproliferative Neoplasms: Diagnosis and TreatmentChronic Myeloid Leukemia TreatmentsKruppel-like factors research